Clinical efficacy of surgery combined with chemotherapy in treatment of platinum sensitive recurrent ovarian cancer

朱颐,吴大保,申震,汪菁,张雪芬

DOI: https://doi.org/10.3969/j.issn.1000-0399.2017.09.010

2017-01-01

Abstract:Objective To evaluate the clinical efficacy of surgery combined with chemotherapy for platinum sensitive recurrent ovarian cancer.Methods From Jan 2013 to Dec 2015,80 patients with platinum sensitive recurrent ovarian cancer in our hospital were divided into operation + chemotherapy group (41 cases) and chemotherapy group (39 cases).The survival rate and fatality rate were compared between the two groups during the 1 year follow-up.The complications,lesions and metastasis of the two groups were compared by routine blood test,color Doppler ultrasound,CT or MRI.Results The average survival time of operation + chemotherapy group and the chemotherapy group was (21.37 ± 5.64) months and (14.22 ± 4.82) months,respectively,and the difference was statistically significant (t =5.83,P =0.00).The mortality rate of operation + chemotherapy group and the chemotherapy group was 34.13％ and 71.82％,respectively,(x2 =1.28,P =0.32).The complication rate of the operation + chemotherapy group and the chemotherapy group was 19.51％ and 30.77％,respectively,(.x2 =11.82,P =0.03).The incidence rate of focus and metastasis in operation + chemotherapy and the chemotherapy group was 35.90％ and 56.41％,respectively,(x2 =2.67,P =0.00).Conclusion Operation combined with chemotherapy has a high clinical effect on platinum sensitive recurrent ovarian cancer and is worth popularization and application.